Description
Lumakras is a prescription medication for treating advanced or metastatic non-small cell lung cancer (NSCLC) with a specific genetic mutation called KRAS G12C. This mutation is present in about 13% of NSCLC cases and has historically been difficult to target with traditional treatments.
Lumakras works by inhibiting the activity of the mutated KRAS protein, which is a gene responsible for the uncontrolled growth and spread of cancer cells. Lumakras attaches to the protein made by this gene mutation, rendering the protein inactive, which inhibits cancerous cell growth.
Fact Table |
Formula |
C30H30F2N6O3 |
License |
US DailyMed |
Bioavailability |
- |
Legal status |
Rx-Only |
Chemical Name |
Sotorasib |
Elimination half-life |
5 hours |
Dosage (Strength) |
120mg |
Pregnancy |
Consult Doctor |
Brands |
Lumakras |
Protein binding |
- |
PubChem CID |
137278711 |
MedlinePlus |
a621036 |
ChEBI |
178199 |
ATC code |
L01XX73 |
DrugBank |
DB15569 |
KEGG |
D12055 |
Routes of administration |
By mouth |
Directions
The usual dosage is 960 mg by mouth once daily. Lumakras should be taken with or without food.
Ingredients
The active ingredient is Sotorasib.
Interactions
Common drug-drug interactions include:
- Abemaciclib
- Antihepaciviral Combination Products
- Asunaprevir
- Avacopan
- Avanafil
- Avapritinib
- Axitinib
- Bedaquiline
- Elacestrant
- Elbasvir and Grazoprevir
- Encorafenib
- Entrectinib
- Fedratinib
- Fexinidazole
- Finerenone
- Flibanserin
- Ganaxolone
- Lumateperone
- Lurbinectedin
- Mavacamten
- Mobocertinib
- Neratinib
- Nirmatrelvir and ritonavir
- Lovastatin
- Simeprevir
- Sonidegib
- Tazemetostat
- Topotecan
Cautions
Do not use Lumakras if you do not have the KRAS G12C mutation. It is not effective in treating other types of lung cancer.
Tell your healthcare provider if you have a history of lung or breathing problems before using Lumakras. The medication can cause lung inflammation, which can be serious or life-threatening.
Your healthcare provider should administer a liver function test every three weeks for the first three months of treatment.
Side Effects
Common side effects may include:
- Edema
- Skin rash
- Decreased serum albumin
- Decreased serum calcium
- Decreased serum sodium
- Abdominal pain
- Decreased appetite
- Diarrhea
- Nausea
- Vomiting
- Increase in urinary protein
- Decreased hemoglobin
- Lymphocytopenia
- Prolonged partial thromboplastin time
- Hepatotoxicity
- Increased serum alanine aminotransferase
- Increased serum alkaline phosphatase
- Increased serum aspartate aminotransferase
- Fatigue
- Arthralgia
- Musculoskeletal pain
- Cough
- Dyspnea
- Pneumonia
- Cardiac failure
- Gastric ulcer
- Interstitial pulmonary disease
- Pneumonitis
- Respiratory failure
References
- Lumakras [package insert]. Thousand Oaks, CA: Amgen; 2021.
About Dr. Conor Sheehy (Page Author)
Dr. Sheehy (BSc Molecular Biology, PharmD) works a clinical pharmacist specializing in cardiology, oncology, and ambulatory care. He’s a board-certified pharmacotherapy specialist (BCPS), and his experience working one-on-one with patients to fine tune their medication and therapy plans for optimal results makes him a valuable subject matter expert for our pharmacy. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 13778